|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US7090843B1
(en)
†
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
CA2467242A1
(en)
*
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
WO2003055527A2
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
|
EP1471938A4
(en)
*
|
2002-01-09 |
2008-03-05 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
SI1545613T1
(sl)
*
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2006039644A2
(en)
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating cd30 positive lymphomas
|
|
WO2006089232A2
(en)
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking fucosyl residues
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
US8257706B2
(en)
*
|
2006-08-25 |
2012-09-04 |
Seattle Genetics, Inc. |
CD30 binding agents and uses thereof
|
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
EP2185188B1
(en)
|
2007-08-22 |
2014-08-06 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
|
|
CN101969970B
(zh)
|
2007-10-12 |
2014-10-15 |
西雅图基因公司 |
用抗体-药物偶联物联合治疗
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
CA3159253A1
(en)
|
2009-01-09 |
2010-07-15 |
Seagen Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
KR101224468B1
(ko)
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
AU2011316917B2
(en)
|
2010-10-22 |
2016-02-25 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
|
|
US9764038B2
(en)
|
2011-12-23 |
2017-09-19 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
CN117264057A
(zh)
*
|
2012-04-27 |
2023-12-22 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
US10036010B2
(en)
|
2012-11-09 |
2018-07-31 |
Innate Pharma |
Recognition tags for TGase-mediated conjugation
|
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
RU2015129800A
(ru)
|
2012-12-21 |
2017-01-30 |
Биоэллаенс К. В. |
Гидрофильные саморазрушающиеся линкеры и их конъюгаты
|
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
KR20220041957A
(ko)
|
2013-03-15 |
2022-04-01 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
항-egfr 항체 약물 접합체 제형
|
|
CN105209076A
(zh)
|
2013-03-15 |
2015-12-30 |
阿布维公司 |
抗体药物偶联物(adc)纯化
|
|
EP2983790A2
(en)
|
2013-04-09 |
2016-02-17 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
ポリペプチドの酵素的結合
|
|
ES2826398T3
(es)
|
2013-10-15 |
2021-05-18 |
Seagen Inc |
Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
|
|
JP2017510548A
(ja)
|
2014-01-29 |
2017-04-13 |
シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
|
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
SG11201610620UA
(en)
|
2014-06-20 |
2017-01-27 |
Bioalliance Cv |
Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
AU2016271124C1
(en)
|
2015-05-30 |
2020-05-14 |
Molecular Templates, Inc. |
De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
|
CN112125929A
(zh)
|
2015-06-15 |
2020-12-25 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
|
FI3319936T3
(fi)
|
2015-07-12 |
2026-03-12 |
Hangzhou Dac Biotech Co Ltd |
Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US10711282B2
(en)
|
2015-11-23 |
2020-07-14 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
SG11201805557SA
(en)
|
2016-01-08 |
2018-07-30 |
Bioalliance Cv |
Tetravalent anti-psgl-1 antibodies and uses thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
CN110022938A
(zh)
|
2016-11-14 |
2019-07-16 |
千禧制药公司 |
抗cd30抗体药物缀合物的非成年人给药
|
|
CA3042442C
(en)
|
2016-11-14 |
2024-01-02 |
Hangzhou Dac Biotech Co., Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US20210330801A1
(en)
|
2017-03-02 |
2021-10-28 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
|
AU2018237683A1
(en)
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EP3694559A2
(en)
|
2017-10-11 |
2020-08-19 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
MX2020004229A
(es)
|
2017-10-25 |
2020-07-22 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019089870A1
(en)
|
2017-11-01 |
2019-05-09 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
CN117003874A
(zh)
|
2018-03-20 |
2023-11-07 |
鸿运华宁（杭州）生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
|
|
CA3093731A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3856777A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
|
WO2020063676A1
(zh)
|
2018-09-26 |
2020-04-02 |
江苏恒瑞医药股份有限公司 |
依喜替康类似物的配体-药物偶联物及其制备方法和应用
|
|
MX2021003734A
(es)
|
2018-10-01 |
2021-07-16 |
Seagen Inc |
Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
|
|
US11279698B2
(en)
|
2018-11-20 |
2022-03-22 |
Cornell University |
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
CN112125915A
(zh)
|
2019-09-18 |
2020-12-25 |
四川百利药业有限责任公司 |
一种喜树碱衍生物及其偶联物
|
|
KR20220069964A
(ko)
|
2019-09-25 |
2022-05-27 |
씨젠 인크. |
조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
AU2020356955A1
(en)
|
2019-10-04 |
2022-04-14 |
Seagen Inc. |
Camptothecin peptide conjugates
|
|
AU2020379001A1
(en)
|
2019-11-04 |
2022-06-09 |
Paul RUBINSTEIN |
Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
CN118949063A
(zh)
|
2020-01-22 |
2024-11-15 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
|
MX2022009389A
(es)
|
2020-01-31 |
2022-10-13 |
Seagen Inc |
Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin.
|
|
JP7689979B2
(ja)
|
2020-03-25 |
2025-06-09 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体を含む医薬組成物及びその使用
|
|
BR112022019042A2
(pt)
|
2020-03-25 |
2022-11-01 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Método de preparação para conjugado anticorpo-fármaco
|
|
WO2021207701A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
|
CA3183602A1
(en)
|
2020-05-13 |
2021-11-18 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202246242A
(zh)
|
2021-01-15 |
2022-12-01 |
美商西健公司 |
免疫調節抗體藥物結合物
|
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022262600A1
(en)
|
2021-04-20 |
2023-10-05 |
Seagen Inc. |
Modulation of antibody-dependent cellular cytotoxicity
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
CA3221398A1
(en)
|
2021-05-28 |
2022-12-01 |
Seagen Inc. |
Anthracycline antibody conjugates
|
|
IL312110A
(en)
|
2021-10-29 |
2024-06-01 |
Seagen Inc |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
CN114891101B
(zh)
*
|
2021-12-02 |
2023-06-16 |
吉林省农业科学院 |
一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
|
|
IL315508A
(en)
|
2022-03-17 |
2024-11-01 |
Seagen Inc |
Camptothecin conjugates
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
EP4606385A1
(en)
|
2022-10-18 |
2025-08-27 |
Meiji Seika Pharma Co., Ltd. |
Therapeutic agent for t cell tumor
|
|
CN120112650A
(zh)
|
2022-10-26 |
2025-06-06 |
诺华股份有限公司 |
慢病毒配制品
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
TW202500193A
(zh)
|
2023-03-22 |
2025-01-01 |
美商信立泰生物醫藥公司 |
抗５ｔ４抗原結合結構域、抗體－藥物共軛體及彼等之使用方法
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025090774A1
(en)
|
2023-10-24 |
2025-05-01 |
Seagen Inc. |
Chemotherapeutic compounds and methods of use
|
|
WO2025096626A1
(en)
|
2023-10-31 |
2025-05-08 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025169056A1
(en)
|
2024-02-06 |
2025-08-14 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
CN119331093B
(zh)
*
|
2024-11-04 |
2025-07-11 |
武汉伊莱瑞特生物科技股份有限公司 |
一种抗CD30的兔源Fab抗体及其制备方法和应用
|